Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Peginterferon alfa-2a + ribavirin for HCV in end-stage renal disease (with or without HIV)
2010-023245-30Phase 4Completed
- Sponsor
- National Institute for Infectious Diseases Lazzaro Spallanzani
- Start
- Dec 2010
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of peginterferon alfa-2a and ribavirin in hepatitis C virus infection, human immunodeficiency virus infection (HIV) and end-stage kidney disease (ESKD), sponsored by National Institute for Infectious Diseases Lazzaro Spallanzani. Primary endpoints: Safety, efficacy and tolerability of Peginterferon alfa-2a + ribavirin and Sustained virological response (SVR) at 6 months post-treatment. Started Dec 2010; status: completed.
02
Drugs
peginterferon alfa-2aribavirin
03
Conditions
hepatitis C virus infectionhuman immunodeficiency virus infection (HIV)end-stage kidney disease (ESKD)
Beyond the preview
Go deeper on 2010-023245-30.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-023245-30.